Prediction models are developed to aid health-care providers in estimating the probability or risk that a specific disease or condition is present (diagnostic models) or that a specific event will occur in the future (prognostic models), to inform their decision making. However, the overwhelming evidence shows that the quality of reporting of prediction model studies is poor. Only with full and clear reporting of information on all aspects of a prediction model can risk of bias and potential usefulness of prediction models be adequately assessed. The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Initiative developed a set of recommendations for the reporting of studies developing, validating, or updating a prediction model, whether for diagnostic or prognostic purposes. This article describes how the TRIPOD Statement was developed. An extensive list of items based on a review of the literature was created, which was reduced after a Web-based survey and revised during a 3-day meeting in June 2011 with methodologists, health-care professionals, and journal editors. The list was refined during several meetings of the steering group and in e-mail discussions with the wider group of TRIPOD contributors. The resulting TRIPOD Statement is a checklist of 22 items, deemed essential for transparent reporting of a prediction model study. The TRIPOD Statement aims to improve the transparency of the reporting of a prediction model study regardless of the study methods used. The TRIPOD Statement is best used in conjunction with the TRIPOD explanation and elaboration document. To aid the editorial process and readers of prediction model studies, it is recommended that authors include a completed checklist in their submission (also available at www.tripod-statement.org).
In medicine, patients with their care providers are confronted with making numerous decisions on the basis of an estimated risk or probability that a specific disease or condition is present (diagnostic setting) or a specific event will occur in the future (prognostic setting) (Box A). In the diagnostic setting, the probability that a particular disease is present can be used, for example, to inform the referral of patients for further testing, initiate treatment directly, or reassure patients that a serious cause for their symptoms is unlikely. In the prognostic setting, predictions can be used for planning lifestyle or therapeutic decisions based on the risk for developing a particular outcome or state of health within a specific period (Steyerberg, 2009; Moons et al, 2009b) . Such estimates of risk can also be used to risk-stratify participants in therapeutic clinical trials (Hayward et al, 2006; Dorresteijn et al, 2011) .
In both the diagnostic and prognostic setting, estimates of probabilities are rarely based on a single predictor . Doctors naturally integrate several patient characteristics and symptoms (predictors, test results) to make a prediction (see Box B for differences in common terminology between diagnostic and prognostic studies). Prediction is therefore inherently multivariable. Prediction models (also commonly called 'prognostic models,' 'risk scores,' or 'prediction rules' are tools that combine multiple predictors by assigning relative weights to each predictor to obtain a risk or probability (Steyerberg, 2009; Moons et al, 2009b) . Well-known prediction Box A. Schematic representation of diagnostic and prognostic prediction modeling studies
The nature of the prediction in diagnosis is estimating the probability that a specific outcome or disease is present (or absent) within an individual, at this point in time-that is, the moment of prediction (T ¼ 0). In prognosis, the prediction is about whether an individual will experience a specific event or outcome within a certain time period. In other words, in diagnostic prediction, the interest is in principle a cross-sectional relationship, whereas prognostic prediction involves a longitudinal relationship. Nevertheless, in diagnostic modeling studies, for logistical reasons, a time window between predictor (index test) measurement and the reference standard is often necessary. Ideally, this interval should be as short as possible and without starting any treatment within this period. 
Box B. Similarities and differences between diagnostic and prognostic prediction models
Despite the different nature (timing) of the prediction, there are many similarities between diagnostic and prognostic prediction models, including:
• Type of outcome is often binary: either disease of interest present versus absent (in diagnosis) or the future occurrence of an event yes or no (in prognosis).
• The key interest is to generate the probability of the outcome being present or occurring for an individual, given the values of 2 or more predictors, with the purpose of informing patients and guiding clinical decision making.
• The same challenges as when developing a multivariable prediction model, such as selection of the predictors, model-building strategies, and handling of continuous predictors and the danger of overfitting.
• The same measures for assessing model performance. 
Event definition and event measurement
Loss to follow-up and censoring models include the Framingham Risk Score (Anderson et al, 1991) , Ottawa Ankle Rules (Stiell et al, 1992) , EuroScore (Nashef et al, 1999) , Nottingham Prognostic Index (Haybittle et al, 1982) , and the Simplified Acute Physiology Score (Le Gall et al, 1984) .
PREDICTION MODEL STUDIES
Prediction model studies can be broadly categorised as model development , model validation (with or without updating) (Moons et al, 2012a) , or a combination of both ( Figure 1 ). Model development studies aim to derive a prediction model by selecting the relevant predictors and combining them statistically into a multivariable model. Logistic and Cox regression are most frequently used for short-term (e.g., disease absent vs present, 30-day mortality) and long-term (e.g., 10-year risk) outcomes, respectively (Justice et al, 1999; Steyerberg et al, 2001b; Altman et al, 2009; Royston et al, 2009; Moons et al, 2012a,b) . Studies may also focus on quantifying the incremental or added predictive value of a specific predictor (e.g., newly discovered) to a prediction model . Quantifying the predictive ability of a model on the same data from which the model was developed (often referred to as apparent performance) will tend to give an optimistic estimate of performance, owing to overfitting (too few outcome events relative to the number of candidate predictors) and the use of predictor Development of a prediction model where predictive performance is then directly evaluated using exactly the same data (apparent performance).
Type 1b
Development of a prediction model using the entire data set, but then using resampling (e.g., bootstrapping or cross-validation) techniques to evaluate the performance and optimism of the developed model. Resampling techniques, generally referred to as 'internal validation', are recommended as a prerequisite for prediction model development, particularly if data are limited (6, 14, 15) .
Type 2a
The data are randomly split into two groups: one to develop the prediction model, and one to evaluate its predictive performance. This design is generally not recommended or better than type 1b, particularly in case of limited data, because it leads to lack of power during model development and validation (14, 15, 16) .
Type 2b
The data are nonrandomly split (e.g., by location or time) into two groups: one to develop the prediction model and one to evaluate its predictive performance. Type 2b is a stronger design for evaluating model performance than type 2a, because it allows for nonrandom variation between the 2 data sets (6, 13, 17) .
Type 3
Development of a prediction model using one data set and an evaluation of its performance on separate data (e.g., from a different study).
Type 4
The evaluation of the predictive performance of an existing (published) prediction model on separate data (13).
Types 3 and 4 are commonly referred to as 'external validation studies.' Arguably, type 2b is as well, although it may be considered an intermediary between internal and external validation.
Analysis Type Description
Figure 1. Types of prediction model studies covered by the TRIPOD statement.
Guideline BRITISH JOURNAL OF CANCER selection strategies (Steyerberg et al, 2003) . Studies developing new prediction models should therefore always include some form of internal validation to quantify any optimism in the predictive performance (e.g., calibration and discrimination) of the developed model. Internal validation techniques use only the original study sample and include such methods as bootstrapping or crossvalidation. Internal validation is a necessary part of model development (Steyerberg, 2009) . Overfitting, optimism, and miscalibration may also be addressed and accounted for during the model development by applying shrinkage (e.g., heuristic or based on bootstrapping techniques) or penalisation procedures (e.g., ridge regression or lasso) (Steyerberg et al, 2001a) .
After developing a prediction model, it is strongly recommended to evaluate the performance of the model in other participant data than was used for the model development. Such external validation requires that for each individual in the new data set, outcome predictions are made using the original model (i.e., the published regression formula) and compared with the observed outcomes Moons et al, 2012a) . External validation may use participant data collected by the same investigators, typically using the same predictor and outcome definitions and measurements, but sampled from a later period (temporal or narrow validation); by other investigators in another hospital or country, sometimes using different definitions and measurements (geographic or broad validation); in similar participants but from an intentionally different setting (e.g., model developed in secondary care and assessed in similar participants but selected from primary care); or even in other types of participants (e.g., model developed in adults and assessed in children, or developed for predicting fatal events and assessed for predicting nonfatal events) (Justice et al, 1999; Reilly and Evans, 2006; Wallace et al, 2011; Moons et al, 2012a Moons et al, , 2012b . In case of poor performance, the model can be updated or adjusted on the basis of the validation data set (Moons et al, 2012a) .
REPORTING OF MULTIVARIABLE PREDICTION MODEL STUDIES
Studies developing or validating a multivariable prediction model share specific challenges for researchers . Several reviews have evaluated the quality of published reports that describe the development or validation prediction models (Laupacis et al, 1997; Mallett et al, 2010; Collins et al, 2011; Bouwmeester et al, 2012; Collins et al, 2013 Collins et al, , 2014 . For example, Mallett et al (2010) examined 47 reports published in 2005 presenting new prediction models in cancer. Reporting was found to be poor, with insufficient information described in all aspects of model development, from descriptions of patient data to statistical modeling methods. Collins et al (2011) evaluated the methodological conduct and reporting of 39 reports published before May 2011 describing the development of models to predict prevalent or incident type 2 diabetes. Reporting was also found to be generally poor, with key details on which predictors were examined, the handling and reporting of missing data, and model-building strategy often poorly described. Bouwmeester et al (2012) evaluated 71 reports, published in 2008 in six high-impact general medical journals, and likewise observed an overwhelmingly poor level of reporting. These and other reviews provide a clear picture that, across different disease areas and different journals, there is a generally poor level of reporting of prediction model studies (Laupacis et al, 1997; Ettema et al, 2010; Mallett et al, 2010; Collins et al, 2011; Bouwmeester et al, 2012; Collins et al, 2013; Steyerberg et al, 2013; Collins et al, 2014) . Furthermore, these reviews have shown that serious deficiencies in the statistical methods, use of small data sets, inappropriate handling of missing data, and lack of validation are common (Laupacis et al, 1997; Ettema et al, 2010; Mallett et al, 2010; Collins et al, 2011; Bouwmeester et al, 2012; Collins et al, 2013; Steyerberg et al, 2013; Collins et al, 2014) . Such deficiencies ultimately lead to prediction models that are not or should not be used. It is therefore not surprising, and fortunate, that very few prediction models, relative to the large number of models published, are widely implemented or used in clinical practice .
Prediction models in medicine have proliferated in recent years. Health-care providers and policy makers are increasingly recommending the use of prediction models within clinical practice guidelines to inform decision making at various stages in the clinical pathway (Rabar et al, 2012; Goff et al, 2014) . It is a general requirement of reporting of research that other researchers can, if required, replicate all the steps taken and obtain the same results (Laine et al, 2007) . It is therefore essential that key details of how a prediction model was developed and validated be clearly reported to enable synthesis and critical appraisal of all relevant information (Knottnerus, 1995; Altman et al, 2009; Collins and Moons, 2012; Seel et al, 2012; Siontis et al, 2012) .
REPORTING GUIDELINES FOR PREDICTION MODEL STUDIES: THE TRIPOD STATEMENT
We describe the development of the TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) Statement, a guideline specifically designed for the reporting of studies developing or validating a multivariable prediction model, whether for diagnostic or prognostic purposes. TRIPOD is not intended for multivariable modeling in etiologic studies or for studies investigating single prognostic factors (McShane et al, 2005) . Furthermore, TRIPOD is also not intended for impact studies that quantify the impact of using a prediction model on participant or doctors' behavior and management, participant health outcomes, or cost-effectiveness of care, compared with not using the model (Moons et al, 2009a (Moons et al, , 2012a .
Reporting guidelines for observational (the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE)) , tumor marker (REporting recommendations for tumour MARKer prognostic studies (REMARK)) (McShane et al, 2005) , diagnostic accuracy (STAndards for the Reporting of Diagnostic accuracy studies (STARD)) (Bossuyt et al, 2003) , and genetic risk prediction (Genetic RIsk Prediction Studies (GRIPS)) (Janssens et al, 2011b ) studies all contain many items that are relevant to studies developing or validating prediction models. However, none of these guidelines are entirely appropriate for prediction model studies. The two guidelines most closely related to prediction models are REMARK and GRIPS. However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.
To address a broader range of studies, we developed the TRIPOD guideline: Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis. TRIPOD explicitly covers the development and validation of prediction models for both diagnosis and prognosis, for all medical domains and all types of predictors. TRIPOD also places much more emphasis on validation studies and the reporting requirements for such studies. The reporting of studies evaluating the incremental value of specific predictors, beyond established predictors or even beyond existing prediction models (Tzoulaki et al, 2011; Steyerberg et al, 2012) , also fits entirely within the remit of TRIPOD (see the accompanying explanation and elaboration document (Moons et al, 2015) , available at www.annals.org).
DEVELOPING THE TRIPOD STATEMENT
We convened a 3-day meeting with an international group of prediction model researchers, including statisticians, epidemiologists, methodologists, health-care professionals, and journal editors (from Annals of Internal Medicine, BMJ, Journal of Clinical Epidemiology, and PLoS Medicine) to develop recommendations for the TRIPOD Statement.
We followed published guidance for developing reporting guidelines and established a steering committee (Drs Collins, Reitsma, Altman, and Moons) to organise and coordinate the development of TRIPOD (Moher et al, 2010) . We conducted a systematic search of MEDLINE, EMBASE, PsychINFO, and Web of Science to identify any published articles making recommendations on reporting of multivariable prediction models (or aspects of developing or validating a prediction model), reviews of published reports of multivariable prediction models that evaluated methodological conduct or reporting and reviews of methodological conduct and reporting of multivariable models in general. From these studies, a list of 129 possible checklist items was generated. The steering committee then merged related items to create a list of 76 candidate items.
Twenty-five experts with a specific interest in prediction models were invited by e-mail to participate in the Web-based survey and to rate the importance of the 76 candidate checklist items. Respondents (24 of 27) included methodologists, health-care professionals, and journal editors. (In addition to the 25 meeting participants, the survey was also completed by 2 statistical editors from Annals of Internal Medicine.)
The results of the survey were presented at a 3-day meeting in June 2011, in Oxford, United Kingdom; it was attended by 24 of the 25 invited participants (22 of whom had participated in the survey). During the 3-day meeting, each of the 76 candidate checklist items was discussed in turn, and a consensus was reached on whether to retain, merge with another item, or omit the item. Meeting participants were also asked to suggest additional items. After the meeting, the checklist was revised by the steering committee during numerous face-to-face meetings, and circulated to the participants to ensure it reflected the discussions. While making revisions, conscious efforts were made to harmonise our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items (McShane et al, 2005; von Elm et al, 2007; Little et al, 2009; Moher et al, 2009; Janssens et al, 2011b) .
TRIPOD COMPONENTS
The TRIPOD Statement is a checklist of 22 items that we consider essential for good reporting of studies developing or validating multivariable prediction models (Table 1 ). The items relate to the title and abstract (items 1 and 2), background and objectives (item 3), methods (items 4 through 12), results (items 13 through 17), discussion (items 18 through 20), and other information (items 21 and 22). The TRIPOD Statement covers studies that report solely development , Moons et al, 2012b , both development and external validation, and solely external validation (with or without updating), of a prediction model (Figure 1) . Therefore, some items are relevant only for studies reporting the development of a prediction model (items 10a, 10b, 14, and 15) , and others apply only to studies reporting the (external) validation of a prediction model (items 10c, 10e, 12, 13c, 17, and 19a) . All other items are relevant to all types of prediction model development and validation studies. Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, whereas items relating to both types of study are denoted D;V.
The recommendations within TRIPOD are guidelines only for reporting research and do not prescribe how to develop or validate a prediction model. Furthermore, the checklist is not a quality assessment tool to gauge the quality of a multivariable prediction model.
An ever-increasing number of studies are evaluating the incremental value of specific predictors, beyond established predictors or even beyond existing prediction models (Tzoulaki et al, 2011; Steyerberg et al, 2012) . The reporting of these studies fits entirely within the remit of TRIPOD (see accompanying explanation and elaboration document (Moons et al, 2015) .
THE TRIPOD EXPLANATION AND ELABORATION DOCUMENT
In addition to the TRIPOD Statement, we produced a supporting explanation and elaboration document (Moons et al, 2015) in a similar style to those for other reporting guidelines Janssens et al, 2011a; Altman et al, 2012) . Each checklist item is explained and accompanied by examples of good reporting from published articles. In addition, because many such studies are methodologically weak, we also summarise the qualities of good (and the limitations of less good) studies, regardless of reporting (Moons et al, 2015) . A comprehensive evidence base from existing systematic reviews of prediction models was used to support and justify the rationale for including and illustrating each checklist item. The development of the explanation and elaboration document was completed after several face-to-face meetings, teleconferences, and iterations among the authors. Additional revisions were made after sharing the document with the whole TRIPOD group before final approval.
ROLE OF THE FUNDING SOURCE
There was no explicit funding for the development of this checklist and guidance document. The consensus meeting in June 2011 was partially funded by a National Institute for Health Research Senior Investigator Award held by Dr Altman, Cancer Research UK, and the Netherlands Organization for Scientific Research. Drs Collins and Altman are funded in part by the Medical Research Council. Dr Altman is a member of the Medical Research Council Prognosis Research Strategy (PROGRESS) Partnership. The funding sources had no role in the study design, data collection, analysis, preparation of the manuscript, or decision to submit the manuscript for publication.
DISCUSSION
Many reviews have showed that the quality of reporting in published articles describing the development or validation of multivariable prediction models in medicine is poor (Laupacis et al, 1997; Ettema et al, 2010; Mallett et al, 2010; Collins et al, 2011; Bouwmeester et al, 2012; Collins et al, 2013 Collins et al, , 2014 . In the absence of detailed and transparent reporting of the key study details, it is difficult for the scientific and health-care community to objectively judge the strengths and weaknesses of a prediction model study (Collins and Michaëlsson, 2012; Seel et al, 2012; Järvinen et al, 2014) . The explicit aim of this checklist is to improve the quality of reporting of published prediction model studies. The TRIPOD guideline has been developed to support authors in writing reports describing the development, validation, or updating of prediction models, aid editors and peer reviewers in reviewing Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD explanation and elaboration document.
manuscripts submitted for publication, and help readers in critically appraising published reports. The TRIPOD Statement does not prescribe how studies developing, validating, or updating prediction models should be undertaken, nor should it be used as a tool for explicitly assessing quality or quantifying risk of bias in such studies . There is, however, an implicit expectation that authors have an appropriate study design and conducted certain analyses to ensure all aspects of model development and validation are reported. The accompanying explanation and elaboration document describes aspects of good practice for such studies, as well as highlighting some inappropriate approaches that should be avoided (Moons et al, 2015) .
TRIPOD encourages complete and transparent reporting reflecting study design and conduct. It is a minimum set of information that authors should report to inform the reader about how the study was carried out. We are not suggesting a standardised structure of reporting, rather that authors should ensure that they address all the checklist items somewhere in their article with sufficient detail and clarity.
We encourage researchers to develop a study protocol, especially for model development studies, and even register their study in registers that accommodate observational studies (such as ClinicalTrials.gov) (Hemingway et al, 2009; Williams et al, 2010) . The importance of also publishing protocols for developing or validating prediction models, certainly when conducting a prospective study, is slowly being acknowledged (Stiell et al, 2002a,b) . Authors can also include the study protocol when submitting their article for peer review, so that readers can know the rationale for including individuals into the study or whether all of the analyses were prespecified.
To help the editorial process, peer reviewers, and, ultimately, readers, we recommend submitting the checklist as an additional file with the report, indicating the pages where information for each item is reported. The TRIPOD reporting template for the checklist can be downloaded from www.tripod-statement.org.
Announcements and information relating to TRIPOD will be broadcasted on the TRIPOD Twitter address (@TRIPOD Statement). The Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network (www.equator-network.org) will help disseminate and promote the TRIPOD Statement.
Methodological issues in developing, validating, and updating prediction models evolve. TRIPOD will be periodically reappraised, and if necessary, modified to reflect comments, criticisms, and any new evidence. We therefore encourage readers to make suggestions for future updates so that ultimately, the quality of prediction model studies will improve.
